2017

FIDIA PHARMA USA Inc. Continues to Expand U.S. Presence as Fidia Farmaceutici S.p.A. Leads European Orthopedic Biomaterials Market

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021
PARSIPPANY, N.J., June 28, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is anticipated

Read More

HYMOVIS®: An Innovation In Ha-Based Viscoelastic Hydrogel Technology In The Treatment Of Osteoarthritis Knee Pain

PARSIPPANY, NJ, May 8, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA) – based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces their presence at the American Medical Society for Sports Medicine (AMSSM) 2017 Annual Meeting with an educational symposium on Thursday, May […]

Read More

HYMOVIS® Demonstrates Superior Biomechanical Lubricating Properties

HYMOVIS® has exceptional lubricating properties in moving cartilage to a low-friction regime. The study provides a unifying framework to evaluate the potential clinical efficacy of injectable hyaluronic acid therapies. PARSIPPANY, NJ., March 22, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA) – based products and […]

Read More

Our Four Leading Principles:

Innovation

Quality

Globalization

Competitiveness